Viral Vectors and Plasmid DNA Manufacturing Market In-Depth Analysis Globally by Top Key Players
The global viral vector and plasmid DNA manufacturing market
is driven by the rising demand for viral vector-based vaccines for infectious
diseases and a shift in the treatment paradigm of several life-threatening
diseases through advanced the rapies and technological advancements in viral
vectors.Severalkey players are dominating the global viral vector and plasmid
DNA manufacturing market, contributing to a significant revenue share.
According to MRFR analysis, the global viral
vector and plasmid DNA manufacturing market is expected to register a CAGR
of ~16.9% from 2021 to 2027 and hold a value of ~USD 4,870 million in2027.The
prominent players are involved in organic and inorganic strategies such
asagreements, new product development & launches, mergers &
acquisitions, joint venntures, collaborations, partnershipsand geographic
expansions, to sustaintheir market positions.For instance,in April 2021, Albumedix (UK) extended
itsresearch collaboration with Cobra Biologics (US) for the upstream and
downstream processing of AAV and lentiviral vector. The collaboration was
intended for stability enhancement and process optimization by the company.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/10679
Key Players
Some of the key players in the global Viral Vector and
Plasmid DNA Manufacturing market are Cognate BioServices, Inc. (US), Catalent
Pharma Solutions (US), Fujifilm Holdings Corporation (Japan), Johnson &
Johnson (US), Sanofi Corporation (France), F. Hoffmann-LA Roche Ltd
(Switzerland), 4D Molecular Therapeutics (US), Sirion Biotech GmbH (Germany),
Voyager Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Gene Therapy Catapult
(UK), UniQure (Netherlands), MassBiologics (US), Renova Therapeutics (US) and
Shenzhen SiBionoGeneTech Co., Ltd (China).
Segmentation
The global viral vector and plasmid DNA manufacturing market
has been segmented intovector type, workflow, disease type, application, and
end user.
By vector type, the market is segmented into plasmid DNA,
viral vector, non-viral vector. The viral vector segment represented the
dominant share in 2020, owing to the rising prevalence of target diseases and
disorders, the effectiveness of viral vectors in gene therapy delivery, and
rising research activities focused on viral vector-based gene & cell
therapies.
Based on the workflow, the market is segmented into upstream
processing, downstream processing. Downstream processing dominated the market
for viral vectors and plasmid DNA manufacturing in 2020. Increasing adoption of
downstream processing methods to help reduce contaminants originating from host
cells or culture media is driving the market growth of this segment.
On the basis of disease type, the market has been segmented
into genetic disorders, cancer, infectious diseases, and others. Cancer held
the largest market share in 2020 due to the increasing prevalence of cancer
cases globally. Furthermore, geneticdisordersare expected to be the
fastest-growing segment.
Based on application, the market is segmented into antisense
& RNAi therapy, gene therapy, cell therapy, vaccinology, and research. The
vaccinology segment dominated the market in 2020, owing tothe rising adoption
of viral vectors in vaccine development.
By end user, pharmaceutical & biopharmaceutical
companies and research institutes. Research institutes held a major share in
the global viral vectors and plasmid DNA manufacturing market. The increasing
number of research centers in gene and cell therapy coupled with rising
research activities for viral vectors and plasmid DNA is projected to increase
the demand for viral vectors in the global market.
Regional Analysis
Based on region, North America is expected to dominate the
global viral vector and plasmid DNA manufacturing market in 2020. Factors such
as the presence of a largenumber of centers and institutes engaged in the
R&D of advanced therapies and key players in this region involved in new
product launches, expansion, acquisition,and strategic collaborations are
driving the market growth. For instance, In March 2021, ABECMA
(idecabtagenevicleucel), a lentivirus-based gene therapy, received the US FDA
approvalto treat R/R multiple myeloma.
Europe is expected to hold the second-largest position in
the global viral vector and plasmid DNA manufacturing market in 2021. Key
factors attributing to the market growth are the increasing R&D spendings
to enhance research activities in the healthcare industry. For instance,
according to the data published in Eurostat in 2018, the EU spent approximately
348 USD million on Research & Development. The R&D expenditure as a
percentage of GDP was 2.18% in 2018, compared to 1.87 % in 2008.
Asia-Pacific is anticipated to be the fastest-growing
regional market over the assessment period due to the increasing prevalence of
target disorders and healthcare needs. Furthermore, the growth of the market in
the rest of the world is attributed to the rising penetration of advanced
healthcare technologies in research organizations focused on viral vector and
plasmid DNA manufacturing incountries such as Saudi Arabia and the UAE.
Developing countries such as Argentina, Brazil, and Colombia, among others in
Latin America, are also key contributors to the growth of the market.
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/viral-vectors-and-plasmid-dna-manufacturing-market-10679
About Market
Research Future:
At Market Research
Future (MRFR), we enable our customers to unravel the complexity of various
industries through our Cooked Research Report (CRR), Half-Cooked Research
Reports (HCRR), & Consulting Services. MRFR team have supreme objective to
provide the optimum quality market research and intelligence services to our
clients.
Contact:
Akash Anand
Market Research
Future
+1 646 845 9312
Comments
Post a Comment